



GEORGIA DEPARTMENT  
OF COMMUNITY HEALTH

# Georgia Department of Community Health

## DRUG UTILIZATION REVIEW BOARD MEETING

Department of Community Health

**April 17, 2024**



## TABLE OF CONTENTS

Item 1	Agenda
Item 2	Minutes and Votes
Item 3	DCH Decisions
Item 4	Manufacturer Information <ul style="list-style-type: none"><li>- Manufacturer Input Opportunities</li><li>- Manufacturers' Forum Drug Summaries</li></ul>
Item 5	New Drug Reviews <ul style="list-style-type: none"><li>- New Drugs Chart</li><li>- Izervay</li><li>- Litfulo</li><li>- Miebo</li><li>- Zurzuvae</li></ul>
Item 6	Preferred Drug List
Item 7	Upcoming Meetings
Item 8	DURB Members



**DRUG UTILIZATION REVIEW BOARD MEETING  
AGENDA**

*2 Martin Luther King Jr. Drive, S.E.  
Atlanta, Georgia 30334*

*Department of Community Health Board Room - Room 470-A  
East Tower, Balcony Level*

**Wednesday, April 17, 2024  
10:00 a.m. to 2:00 p.m.**

<b>CALL TO ORDER</b>	<i>Celeste Fowler, PharmD, MBA, Chair</i>
<b>MINUTES FROM PREVIOUS MEETING</b>	<i>Chair</i>
<b>EXTERNAL COMMENTS SESSION</b>	<i>Chair</i>
<b>CLINICAL REVIEWS</b>	<i>Chad Nicholson, PharmD, NorthStar Emily Baker, PharmD, BCPS, NorthStar</i>
➤ <b>New Drugs</b>	
● Izervay	
● Litfulo	
● Miebo	
● Zurzuvae	
<b>ADJOURNMENT OF OPEN SESSION</b>	<i>Chair</i>
<b>EXECUTIVE SESSION</b>	<i>Afzal Mistry, PharmD, Magellan Rx Nina Bandali, PharmD, Magellan Rx</i>
<b>RECONVENING OF OPEN SESSION</b>	<i>Chair</i>
<b>BOARD'S RECOMMENDATIONS AND VOTES</b>	<i>Chair</i>
<b>FUTURE AGENDA ITEMS</b>	<i>Chair</i>
<b>ADJOURNMENT OF MEETING</b>	<i>Chair</i>

**Department of Community Health  
Drug Utilization Review Board (DURB)  
MINUTES  
Wednesday, January 17, 2024**

**MEMBERS PRESENT**

M. Celeste Fowler, Pharm.D., HCMBA, Chair  
Alton Condra, III, R.Ph.  
Torey Jones, Pharm.D.  
Burton L. Lesnick, M.D., FAAP  
J. Russell (Rusty) May, Pharm.D.  
Osgood (Drew) A. Miller, R.Ph.  
Suzanne Walton, Pharm.D., BCPS, BCOP

**MEMBERS ABSENT**

Gurinder Doad, M.D., Ph.D., Vice-Chair  
Doug Collins, M.D.  
Glenda Wrenn Gordon, M.D., MSHP, FAPA  
Otto Goyco, M.D.  
Robyn Lorys, Pharm.D.  
Matthew Perri, Pharm.D., R.Ph., Ph.D.  
Brent L. Rollins, R.Ph., Ph.D.  
Danny A. Toth, R.Ph.

**Staff**

Peter D'Alba, Pharm.D., Pharmacy Director, Pharmacy Services  
Gilletta Gray, R.Ph., Clinical Manager, Pharmacy Services  
Ashlee Henry, MSHI, Pharmacy Operations Supervisor  
Ashley Bellino, Pharmacy Operations Specialist, Pharmacy Services  
Rose Duncan, MBA, Operations Analyst-Drug Rebate Program, Pharmacy Services  
Lori Garner, MHS, MBA, R.Ph., Pharmacist, SHBP

**NorthStar HealthCare Consulting**

Emily Baker, Pharm.D., BCPS, MHA, MBA, President  
Afzal "Fez" Mistry, Pharm.D., Clinical Programs Director  
Chad Nicholson, Pharm.D., Clinical Pharmacist  
Catherine "Amy" Baker, Pharm.D., Clinical Pharmacist

**OptumRx**

Mark Hall, MBA, PMP, Assoc. Director, Government and Public Sector Markets  
Talmahjia "Tami" Sweat, Pharm.D., Clinical Consulting

**Magellan Rx Management**

Nina Bandali, Pharm.D., Pharmacist Account Manager

**Care Management Organizations**

Cassandra Tancil, Pharm.D., BCPS, Amerigroup  
Charles Kim, Pharm.D., PeachState

MINUTES

Wednesday, January 17, 2024

**Call to Order**

The Drug Utilization Review Board (DURB/DUR Board/Board) held its first meeting for the calendar year on January 17, 2024. The Chair, M. Celeste Fowler, Pharm.D., HCMBA, called the meeting to order at 10:03am after Board members introduced themselves.

**Minutes from the Previous Meeting**

Chair Fowler asked for corrections or changes to the minutes from the September 26, 2023 meeting. A motion was made (Burton L. Lesnick, M.D., FAAP) and seconded (J. Russell (Rusty) May, Pharm.D.) and carried to approve the minutes as written.

**External Comments Session**

The following external comment was presented to the Board:

- Nathan – shared his story about his son with Duchenne Muscular Dystrophy and his successful treatment experience with Elevidys.

Disclosure forms were completed by Nathan and were reviewed by the Department.

**New Drug Reviews**

Clinical information for the following new drugs, in the market six months or more, was presented for discussion and recommendations. The complete detailed drug summary is in the New Drugs for Review section of the DUR Board binder.

Therapeutic Class	Drugs	Presenter
<b>Duchenne Muscular Dystrophy Treatments</b>	<i>Elevidys</i>	Chad Nicholson, Pharm.D.
<b>Hypoglycemics, SGLT2</b>	<i>Inpefa</i>	Chad Nicholson, Pharm.D.
<b>Hemophilia Treatment</b>	<i>Roctavian</i>	Afzal “Fez” Mistry, Pharm.D.
<b>Estrogen Agents, Oral/Transdermal</b>	<i>Veozah</i>	Afzal “Fez” Mistry, Pharm.D.
<b>Antimigraine Agents, Other</b>	<i>Zavzpret</i>	Afzal “Fez” Mistry, Pharm.D.

**Department of Community Health  
Drug Utilization Review Board (DURB)  
MINUTES**

**Wednesday, January 17, 2024**

The Board discussed the drug information, provided comments, and raised questions on the following:

- Elevidys
  - One time dose; indications for later dosing may be challenging since some may have high antibody titer and functional decline
  - Anti-AAV antibody testing specific to this vector – is commercially available; takes about 4-5 days to come back
  - Microdystrophin – endpoint; duration of effect still being monitored; current treatment duration-5 years
  - 2<sup>nd</sup> dose – no consideration given at this time
  - Clinical outcomes – Phase I and Phase II trials published
- Roctavian
  - Treatment population – most established on Hemlibra (70%) and usually not interested in changing therapy; 30% remaining patients – one-third won't qualify due to antibodies, the other two-thirds could be eligible but might not be interested due to monitoring.
  - Consider cost of the monitoring process.
  - Insertional oncogenesis – risk is low and not a huge concern; if vector remains episomal and subsequent liver damage occurs and cells have regeneration, then half of the cells may not get the episome; for this reason, probably not indicated in children because they are still having hepatocellular proliferation.
- Veozah
  - Impact on symptoms compared to other agents – can't really assess since no head-to-head studies.
  - Drug has only been studied for 12 weeks, so no long-term studies.
- Zavzpret
  - Concomitant use with other nasal sprays – don't recommend use of Afrin before other nasal sprays because of vasoconstriction and decreased absorption.

**DCH Decisions**

DCH Decisions from the September 2023 DUR Board meeting were provided in the DCH Decision section of the DUR Board binder.

**Upcoming Meetings**

The following upcoming meetings were announced:

- Drug Utilization Review Board  
2 Martin Luther King Jr. Drive, SE  
East Tower  
Atlanta, Georgia 30334

Wednesday, April 17, 2024: 10:00am –2:00pm

Wednesday, July 17, 2024: 10:00am –2:00pm

Wednesday, October 16, 2024: 10:00am –2:00pm

Wednesday, January 17, 2024

**Disclosure Forms**

Disclosure forms were received and reviewed by the Department for completeness for all Board members attending the meeting.

**Adjournment of Open Session**

The DUR Board voted to have the Executive Session pursuant to the Open Meetings Act of Georgia Section 50-14-1 – 50-14-6 and pursuant to Federal Law Section 1396R-8B3D. The individuals recorded in attendance with the Board members were from the Department of Community Health, Magellan Rx Management, NorthStar HealthCare Consulting, and OptumRx. A motion was made by Osgood (Drew) A. Miller, R.Ph. and seconded (J. Russell (Rusty) May, Pharm.D.) to approve the closed session. There was a unanimous vote approving the closed session. The Chair, M. Celeste Fowler, Pharm.D., HCMBA, adjourned the open session at approximately 11:46am, at which time members took a break then reconvened for the executive (closed) session.

**Executive Session**

The Executive Session was held from 11:59am to 12:31pm.

**Reconvening of Open Session**

The DUR Board reconvened for the open session at 12:34pm.

**Board's Recommendations to the Department**

After all clinical and financial evaluations and discussions, the DUR Board voted and presented the Department with the following recommendations for changes to the Preferred Drug List (PDL) or Physician Administered Drug List (PADL) as noted in Attachment A. All motions and votes are noted in Attachment B.

**Future Agenda Items**

There were no future agenda items noted.

**Conclusion**

At the conclusion of the open session and no other business for discussion, Chair Fowler adjourned the meeting at 12:40pm.

THESE MINUTES ARE HEREBY APPROVED AND ADOPTED, THIS THE \_\_\_\_\_ DAY  
OF \_\_\_\_\_, 2024.

---

M. Celeste Fowler, Pharm.D., HCMBA, Chair

**Drug Utilization Review Board**  
**Motions - Votes - New Drugs**  
**January 17, 2024**

<b>New Drug</b>		<b>Drug</b>	<b>PDL Status</b>	<b>Motion - Recommendations</b>	<b>Additional Comments</b>	
<b>Duchenne Muscular Dystrophy Treatments</b>		Elevidys (Intravenous Suspension)	N/A	P/PA on PADL		
<b>Board Members - Present</b>		<b>Motion Maker (v)</b>	<b>Seconded By (v)</b>	<b>VOTES</b>		
<i>(Strike out, when absent)</i>				<b>YES (v)</b>	<b>NO (v)</b>	<b>ABSTAIN (v)</b>
1	Collins, Douglas, M.D.					
2	Condra III, Alton, R.Ph.			✓		
3	Doad, Gurinder J.S., M.D., Ph.D.- <b>Vice-Chair</b>					
4	Fowler, M. Celeste, Pharm.D., HCMBBA- <b>Chair</b>					
5	Gordon, Glenda Wrenn, M.D., MSHP, FAPA					
6	Goyco, Otto, M.D.					
7	Jones, Torey, Pharm.D.			✓		
8	Lesnick, Burton, M.D., FAAP	✓		✓		
9	Lorys, Robyn, Pharm.D.					
10	May, J. Russell (Rusty), Pharm.D.			✓		
11	Miller,Osgood (Drew) A., R.Ph.		✓	✓		
12	Perri, Matthew, R.Ph., Pharm.D., Ph.D.					
13	Rollins, Brent L., R.Ph., Ph.D.					
14	Toth, Danny, R.Ph.					
15	Walton, Suzanne, Pharm.D., BCPS, BCOP			✓		
<b>TOTAL</b>				<b>6</b>	<b>0</b>	<b>0</b>
<b>New Drug</b>		<b>Drug</b>	<b>PDL Status</b>	<b>Motion - Recommendations</b>	<b>Additional Comments</b>	
<b>Hypoglycemics, SGLT2</b>		Inpefa (Oral) Tablet	N/A	NP/PA		
<b>Board Members - Present</b>		<b>Motion Maker (v)</b>	<b>Seconded By (v)</b>	<b>VOTES</b>		
<i>(Strike out, when absent)</i>				<b>YES (v)</b>	<b>NO (v)</b>	<b>ABSTAIN (v)</b>
1	Collins, Douglas, M.D.					
2	Condra III, Alton, R.Ph.		✓	✓		
3	Doad, Gurinder J.S., M.D., Ph.D.- <b>Vice-Chair</b>					
4	Fowler, M. Celeste, Pharm.D., HCMBBA- <b>Chair</b>					
5	Gordon, Glenda Wrenn, M.D., MSHP, FAPA					
6	Goyco, Otto, M.D.					
7	Jones, Torey, Pharm.D.			✓		
8	Lesnick, Burton, M.D., FAAP			✓		
9	Lorys, Robyn, Pharm.D.					
10	May, J. Russell (Rusty), Pharm.D.	✓		✓		
11	Miller,Osgood (Drew) A., R.Ph.			✓		
12	Perri, Matthew, R.Ph., Pharm.D., Ph.D.					
13	Rollins, Brent L., R.Ph., Ph.D.					
14	Toth, Danny, R.Ph.					
15	Walton, Suzanne, Pharm.D., BCPS, BCOP			✓		
<b>TOTAL</b>				<b>6</b>	<b>0</b>	<b>0</b>
<b>New Drug</b>		<b>Drug</b>	<b>PDL Status</b>	<b>Motion - Recommendations</b>	<b>Additional Comments</b>	



**Drug Utilization Review Board**  
**Motions - Votes - New Drugs**  
**January 17, 2024**

<b>Hemophilia Treatment</b>		Roctavian (Intravenous) Suspension	N/A	NP/PA on PADL	VOTES	
<b>Board Members - Present</b> <i>(Strike out, when absent)</i>		<b>Motion Maker (v)</b>	<b>Seconded By (v)</b>	<b>YES (v)</b>	<b>NO (v)</b>	<b>ABSTAIN (v)</b>
1	Collins, Douglas, M.D.					
2	Condra III, Alton, R.Ph.		√	√		
3	Doad, Gurinder J.S., M.D., Ph.D.- <b>Vice-Chair</b>					
4	Fowler, M. Celeste, Pharm.D., HCMB A-Chair					
5	Gordon, Glenda Wrenn, M.D., MSHP, FAPA					
6	Goyco, Otto, M.D.					
7	Jones, Torey, Pharm.D.			√		
8	Lesnick, Burton, M.D., FAAP			√		
9	Lorys, Robyn, Pharm.D.					
10	May, J. Russell (Rusty), Pharm.D.			√		
11	Miller, Osgood (Drew) A., R.Ph.	√		√		
12	Perri, Matthew, R.Ph., Pharm.D., Ph.D.					
13	Rollins, Brent L., R.Ph., Ph.D.					
14	Toth, Danny, R.Ph.					
15	Walton, Suzanne, Pharm.D., BCPS, BCOP			√		
			<b>TOTAL</b>	<b>6</b>	<b>0</b>	<b>0</b>
<b>New Drug</b>		Drug	PDL Status	<b>Motion - Recommendations</b>	Additional Comments	
<b>Estrogen Agents, Oral/Transdermal</b>		Veozah (Oral) Tablet	N/A	NP/PA		
<b>Board Members - Present</b> <i>(Strike out, when absent)</i>		<b>Motion Maker (v)</b>	<b>Seconded By (v)</b>	<b>YES (v)</b>	<b>NO (v)</b>	<b>ABSTAIN (v)</b>
1	Collins, Douglas, M.D.					
2	Condra III, Alton, R.Ph.			√		
3	Doad, Gurinder J.S., M.D., Ph.D.- <b>Vice-Chair</b>					
4	Fowler, M. Celeste, Pharm.D., HCMB A-Chair					
5	Gordon, Glenda Wrenn, M.D., MSHP, FAPA					
6	Goyco, Otto, M.D.					
7	Jones, Torey, Pharm.D.			√		
8	Lesnick, Burton, M.D., FAAP			√		
9	Lorys, Robyn, Pharm.D.					
10	May, J. Russell (Rusty), Pharm.D.			√		
11	Miller, Osgood (Drew) A., R.Ph.	√		√		
12	Perri, Matthew, R.Ph., Pharm.D., Ph.D.					
13	Rollins, Brent L., R.Ph., Ph.D.					
14	Toth, Danny, R.Ph.					
15	Walton, Suzanne, Pharm.D., BCPS, BCOP		√	√		
			<b>TOTAL</b>	<b>6</b>	<b>0</b>	<b>0</b>
<b>New Drug</b>		Drug	PDL Status	<b>Motion - Recommendations</b>	Additional Comments	
<b>Antimigraine Agents, Other</b>		Zavzpret (Nasal) Spray	N/A	NP/PA		
<b>Board Members - Present</b> <i>(Strike out, when absent)</i>		<b>Motion Maker (v)</b>	<b>Seconded By (v)</b>	<b>YES (v)</b>	<b>NO (v)</b>	<b>ABSTAIN (v)</b>
1	Collins, Douglas, M.D.					
2	Condra III, Alton, R.Ph.			√		

**Drug Utilization Review Board**  
**Motions - Votes - New Drugs**  
**January 17, 2024**

3	Doad, Gurinder J.S., M.D., Ph.D.- <b>Vice-Chair</b>					
4	Fowler, M. Celeste, Pharm.D., HCMBB- <b>Chair</b>					
5	Gordon, Glenda Wrenn, M.D., MSHP, FAPA					
6	Goyco, Otto, M.D.					
7	Jones, Torey, Pharm.D.			√		
8	Lesnick, Burton, M.D., FAAP	√		√		
9	Lorys, Robyn, Pharm.D.					
10	May, J. Russell (Rusty), Pharm.D.		√	√		
11	Miller, Osgood (Drew) A., R.Ph.			√		
12	Perri, Matthew, R.Ph., Pharm.D., Ph.D.					
13	Rollins, Brent L., R.Ph., Ph.D.					
14	Toth, Danny, R.Ph.					
15	Walton, Suzanne, Pharm.D., BCPS, BCOP			√		
<b>TOTAL</b>				<b>6</b>	<b>0</b>	<b>0</b>

## Listed below are Preferred Drug List changes for the State of Georgia Fee-For-Service Medicaid and PeachCare for Kids Programs

Effective April 1, 2024 (see chart below)\*

DCH rebate vendor, Magellan Medicaid Administration (MMA), has reviewed specific drugs at the January 2024 DURB meeting and corresponding supplemental rebate offers. The Preferred Drug List (PDL)/Provider's Administered Drug List (PADL) decisions/changes for categories reviewed are outlined below. For a full listing of our PDL, go to [www.dch.georgia.gov/pharmacy](http://www.dch.georgia.gov/pharmacy) and select the "Preferred Drug Lists" option; for the PADL, go to <https://www.mmis.georgia.gov/portal/> and select "Provider Information", "Fee Schedule", then "Provider's Administered Drug List."

PREFERRED AGENTS	NON-PREFERRED AGENTS
<b>ANTIMIGRAINE AGENTS, OTHER</b>	
	ZAVZPRET (NASAL) – PA
<b>DUCHENNE MUSCULAR DYSTROPHY TREATMENTS</b>	
ELEVIDYS KIT (INTRAVEN)* – PA	
<b>ESTROGEN AGENTS, ORAL/TRANSDERMAL</b>	
	VEOZAH (ORAL) – PA
<b>HEMOPHILIA TREATMENT</b>	
	ROCTAVIAN (INTRAVEN)* – PA
<b>HYPOGLYCEMICS, SGLT2</b>	
	INPEFA (ORAL) – PA

\*PADL drugs may be subject to a different effective date.



## Georgia Department of Community Health (GDCH) Opportunities for Pharmaceutical Manufacturer Input on Clinical Recommendations and Clinical Management Strategies by the Drug Utilization Review Board

Clinical Information and Clinical Management Strategies relevant to the GDCH Medicaid Fee-For-Service program will be presented to the Drug Utilization Review Board (DURB) at each meeting through OptumRx by its vendor NorthStar HealthCare Consulting (NHC). Manufacturer input on new and existing drugs is welcomed and appreciated using these opportunities. **Please note that new drug entities are generally not reviewed by the DURB until the drug has been on the market for at least 6 months.**

### Ongoing Opportunity:

**DUR Board Meeting Process:** New drugs, therapeutic classes and/or supplemental rebate classes under review will be posted to the DCH website at <http://dch.georgia.gov/durb-meeting-information> approximately 30 days prior to the Manufacturers' Forum. Input specific to the drugs under review from manufacturers are made directly to NHC via [GAMedicaid@nhc-llc.com](mailto:GAMedicaid@nhc-llc.com) and reported as appropriate by NHC at subsequent DURB meetings.

Upon review of information, and based on its expertise and discussions, the DURB makes recommendations to GDCH.

### Opportunity to Appeal to GDCH:

**GDCH Review Process:** DURB recommendations are reviewed by GDCH for final decisions. Manufacturers may request an appeal meeting directly with GDCH after conclusion of each quarterly DURB meeting and **this appeal meeting must be conducted within 10 business days following the DURB meeting.** **Contact: Shirmary Hodges at (404) 656-4044 or [shodges@dch.ga.gov](mailto:shodges@dch.ga.gov)**

### Presentation Opportunity:

**Manufacturers' Forum:** A forum prior to each relevant DURB meeting whereby manufacturers may present:

- 1) Clinical information relevant to a new drug on the market under review by the DURB at the next meeting.
- 2) Clinical information relevant to ongoing NHC/OptumRx clinical management strategies (e.g. review of drug benefit plan designs, new drugs coming to market, new indications, etc.) as deemed necessary by NHC/OptumRx.

Please see the Manufacturers' Forum Announcement at

<http://dch.georgia.gov/durb-meeting-information>.

Questions not addressed in this document may be sent to NorthStar HealthCare Consulting by e-mail: [GAMedicaid@nhc-llc.com](mailto:GAMedicaid@nhc-llc.com)

**2024**

## **Upcoming Meetings**

### **Drug Utilization Review Board Meeting**

2 Martin Luther King Jr. Drive, S.E.

Atlanta, Georgia 30334

Department of Community Health Board Room - Room 470-A

East Tower, Balcony Level

Wednesday, July 17, 2024: 10:00am – 2:00pm

Wednesday, October 16, 2024: 10:00am – 2:00pm

*This page intentionally left blank*

### Drug Utilization Review Board

<b>Board Member</b>	<b>Credentials</b>	<b>Specialty/Area of Expertise</b>	<b>Company Name</b>
<b>M. Celeste Fowler, Chair</b>	Pharm.D., HCMBBA	340B Pharmacy	Piedmont Henry Hospital
<b>Gurinder J.S. Doad, Vice-Chair</b>	M.D., Ph.D.	Family Practice	Southwest Georgia Family Medicine and Mercer University School of Medicine
<b>Douglas C. Collins</b>	M.D.	Hematology/Oncology	Metro Hematology-Oncology, PC
<b>Alton Condra III</b>	R.Ph.	HIV/AIDS Pharmacy - Infectious Disease Program	Grady Memorial Hospital
<b>Otto C. Goyco</b>	M.D., FACP	Internal Medicine	Otto C. Goyco Internal Medicine, LLC
<b>Torey A. Jones</b>	Pharm.D., MBA	340B Pharmacy	Phoebe Putney Health System, Bizzell Group, LLC,
<b>Burton L. Lesnick</b>	M.D., FAAP	Pediatrics/Pediatric Pulmonology	Children's Healthcare of Atlanta
<b>Robyn Lorys</b>	Pharm.D.	Academia - Professor	Mercer University College of Pharmacy
<b>J. Russell May</b>	Pharm.D.	Academia - Professor	University of Georgia College of Pharmacy
<b>Drew A. Miller</b>	R.Ph.	Retail Pharmacy	Wynn's Pharmacy
<b>Matthew Perri III</b>	Ph.D., R.Ph.	Academia - Professor	University of Georgia College of Pharmacy
<b>Brent L. Rollins</b>	R.Ph., Ph.D.	Academia - Professor	Philadelphia College of Osteopathic Medicine School of Pharmacy
<b>Danny A. Toth</b>	R.Ph.	Pharmacy Benefit Plans	Timber Ridge Consultants, LLC
<b>Suzanne M. Walton</b>	Pharm.D., BCPS, BCOF	Hematology/Oncology	Grady Health System
<b>Glenda Wrenn</b>	M.D.	Psychiatry, Academia - Professor	Morehouse School of Medicine